Should Type 2 Diabetes Management Be More of a Priority in Post-Acute Coronary Syndrome Patients?

This symposium took place on 14th September 2015 as part of the 51st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden

Chairperson: Ele Ferrannini1
Speakers: Ele Ferrannini,1 Stephen J Nicholls,2 Jørgen Rungby,3 Jean-Claude Tardif,4 Faiez Zannad5

1. University of Pisa School of Medicine, Pisa, Italy
2. SAHMRI and University of Adelaide, Adelaide, Australia
3. Gentofte University Hospital, Hellerup, Copenhagen, Denmark
4. Montreal Heart Institute Research Centre, Montreal, Quebec, Canada
5. Université de Lorraine and CHU, Vandoeuvre-lès-Nancy, France

Disclosures: Ele Ferrannini has served on advisory boards for Boehringer Ingelheim, Eli Lilly, J&J, Sanofi, MSD, GSK, and Metabolon; has received research grants from Eli Lilly and Boehringer Ingelheim; and has served as a speaker for Takeda. Stephen Nicholls has received research support from AstraZeneca, Amgen, Anthera, Eli Lilly, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, and LipoScience. He has also served as a consultant for, or received honoraria from, AstraZeneca, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Aventis, CSL Behring, Esperion, and Boehringer Ingelheim. Jørgen Rungby has received research support from Merck, Novo Nordisk, and Servier, and has served as consultant for, or received honoraria from, AstraZeneca, Eli Lilly, Novo Nordisk, Merck, Takeda, Janssen, Sanofi-Aventis, and Boehringer Ingelheim. Jean-Claude Tardif has received research grants or honoraria from Roche, AstraZeneca, Pfizer, Merck, Servier, Eli Lilly, Cerenis, Thrasos, and Sanofi. Faiez Zannad has served as a consultant on steering committees, event committees, or data safety monitoring boards for AstraZeneca, Bayer, Boston Scientific, CardioRenal Diagnostics, CVCT, CVRx, Daiichi Sankyo, Eli Lilly, Janssen, Merck, Mitsubishi, Novartis, Pfizer, Quantum Genomics, Relypsa, Resmed, St Jude, Takeda, and ZS Pharma.
Acknowledgements: Writing assistance was provided by Dr Janet R. Davies, Atlantic Medical Writing, and funded by Takeda Pharmaceuticals International GmbH Limited.
Support: The symposium was organised by Takeda Pharmaceuticals International GmbH. All authors received honoraria for the preparation and delivery of their presentations. The views and opinions expressed are those of the authors and not necessarily of Takeda Pharmaceuticals International GmbH.
Citation: EMJ Diabet. 2015;3[1]:31-38.

Meeting Summary

This symposium aimed to address the current issues in the management of patients with Type 2 diabetes (T2D) post-acute coronary syndrome (ACS), bringing together the views of both cardiologists and diabetologists. T2D increases the risk of ACS and is associated with a poorer prognosis for these patients. Although guidelines provide comprehensive recommendations for patients with ACS, specific guidance is lacking following hospital discharge for those with concomitant T2D. As a result, these patients receive suboptimal treatment compared with patients without T2D. The cardiovascular (CV) benefits of intensive glucose lowering alone for those with T2D are uncertain. However, knowledge of the CV safety profiles of available therapies helps diabetologists to provide individualised treatment for their patients. Currently, three studies have reported on the CV safety of dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with T2D. However, active inclusion of patients who are both post-ACS (15–90 days) and at high risk of CV disease (CVD) is rare. Only the DPP-4 alogliptin has been assessed in a CV safety outcome study in patients with this specific profile.

Download (PDF, 520KB)

Comments are closed.